Amicus Therapeutics, located in Cranbury, New Jersey, is an American biopharmaceutical company. The company came into public in the year 2007, and it was under the name FOLD, which is a NASDAQ tiding symbol. Before this was the planned offering and then withdrawal that would have established the company as AMTX. Several capital firms funded the Amicus Therapeutics. The firms include radius ventures new enterprise associates and the radius ventures. The chief executive officer was Crowley since the year 2005. He succeeded Donald as the company’s chairman of the board. However, Donald remained to be with Amicus Therapeutics as the leading independent director.
Amicus Therapeutics is focused on rare and orphan diseases and more specifically on the commonly known diseases as lysosomal storage. The developments by the company are based on chaperone advance replacement therapy. It majorly deals with the development of enzyme replacement therapies. Amicus Therapeutics was arguably found to have the largest portfolio of small molecule pharmacological chaperones in the year 2014.
In February 2014, no marketed product for the company existed (http://weeklyopinion.com/2017/08/amicus-therapeutics-announces-the-launch-of-new-drug/). There was this major candidate, migalastat, a pharmacological chaperone treatment for Fabry diseases. Their drug aims to stabilize mutant alpha-galactosidase. Amicus Therapeutics cannot manufacture on their own but rather requires contract manufacturing. Amicus Therapeutics opened a research site in San Diego as it expanded in the year 2008. The company faced a financial setback as it broke up with the shire in a multi-collaborative in the year 2009. During that time of termination, operations related to financing were done primarily based on placements through redeemable convertible preferred stock. It leads to a concomitant reduction of works.
Amicus Therapeutics received $500000 grant from Foundation to support studies in collaboration with David Geffen School of Medicine at UCLA (YahooFinance). To support clinical work, the company further received $210300 from Alzheimer’s Drug Discovery Foundation in cooperation within the school of medicine via Alzheimer’s disease research center. Callidus biopharma arose as a competitor to Amicus Therapeutics in 2013. Therefore it acquired intellectual property materials for the treatment of Pompe in enzyme replacement therapy.